Navigation Links
Aquavit Pharmaceuticals Adds New Advanced Drug Delivery Technology to Product Portfolio
Date:11/5/2013

NEW YORK, Nov. 5, 2013 /PRNewswire/ -- Aquavit Pharmaceuticals, Inc. has further extended its personalized drug delivery platform by signing a binding preliminary agreement with Huons Co, Ltd. (KOSDAQ: 84110), a leading Korean pharmaceuticals company. The agreement formalizes the strategic partnership between the parties and gives Aquavit the worldwide, perpetual, and unlimited license for global commercialization of a cutting-edge drug-delivery system.

The two companies will be investing up to 20 Million USD to further develop the technology and bring to market the highest standard, GMP manufactured product innovations.

"It is a very exciting technology extension for Aquavit. I can already think of many applications and possibilities," said Dr. Nark K. Roh, a world renowned dermatologist and Medical Director of Leaders Clinic.

Aquavit's integrated platform includes innovative microneedle technology, first-of-its-kind desktop robotics for real-time formulations, and proprietary and personalized compounds and admixtures tied together by an advanced health informatics technology. Recently, Aquavit showcased its platform technology at the Big Data in Pharma Conference (Big Dip 2013) opening the Big Data Applications Session.

Earlier this year, Aquavit in-licensed its first microneedle delivery system, AQT-001 branded as AQUAGOLD® fine touch™. Aquavit holds the perpetual, exclusive, worldwide right to license, sub-license, improve and/or commercialize the AQT series and all derivative intellectual property. The AQT series has FDA, CE Mark and KFDA registration and will commerce global distribution in early 2014.

"We look forward to unveiling this latest technology to the public at the 72nd American Academy of Dermatology Annual Meeting in Denver in March, 2014. We aim to be a leader in personalized treatment options integrating cutting-edge technology, assessment tools, and knowledge of our key opinion leaders," said Sobin Chang, CEO of Aquavit.

About Huons Co., Ltd.
Huons Co, Ltd. (KOSDAQ: 84110) is a leading Korean pharmaceuticals company focusing in the development and distribution of drugs, medical devices and regulated cosmetics. It's areas of strength are Urology Orthopedic Surgery, Anti-Arthritis, Anesthetics, Natural Well-Being Products including Anti-Obesity, Gynecology and related Women's Health and Dental Care. For more information, visit www.huons.com.   

About Aquavit Pharmaceuticals, Inc.
Aquavit Pharmaceuticals is a multi-specialty healthcare company focused on discovering, developing and commercializing innovative pharmaceuticals, medical device, and health technologies adapted for the new personalized health paradigm. For more information, visit www.aquavitpharma.com.


'/>"/>
SOURCE Aquavit Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Aquavit Pharmaceuticals and U-Bio Med Enter Exclusive Worldwide License Agreement for Microneedle Technology (AQT-001)
2. Aquavit Pharmaceuticals Inc. Appoints David Shafer, MD., FACS., New Chief Medical Technology Officer
3. Aquavit Pharmaceuticals forms Alliance Partnership with Accelrys
4. Aquavit and Green Cross Sign Strategic Collaboration MOU on IBX-001 Product Development and Commercialization in Asia
5. Jazz Pharmaceuticals to Present at the 2013 Credit Suisse Healthcare Conference on November 12
6. Immune Pharmaceuticals Appoints Liquidity Provider to Facilitate Trading on NASDAQ OMX Stockholm Exchange
7. Actinium Pharmaceuticals to Host Corporate Update and Virtual Roadshow Conference Call on November 11
8. Valeant Pharmaceuticals Reports 2013 Third Quarter Financial Results
9. Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Thursday, November 7
10. Merrimack Pharmaceuticals Announces Results From A Phase 2 Study Of MM-121 (SAR256212) In Combination With Paclitaxel In Patients With Platinum-Resistant Or Refractory Advanced Ovarian Cancers
11. Anthera Pharmaceuticals Reports 2013 Third Quarter Financial Results, Clinical and Regulatory Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... BOSTON , March 27, 2017 ... pharmaceutical company and Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), ... commercialization of innovative therapies based upon tetracycline chemistry, ... sarecycline for the treatment of moderate to severe ... Sarecycline is a once-daily, oral, narrow spectrum tetracycline-derived ...
(Date:3/27/2017)... 2017  Impax Laboratories, Inc. (NASDAQ: IPXL)today announced that ... Bisaro as Impax,s President and Chief Executive Officer ... 27, 2017. Mr. Bisaro will succeed J. Kevin ... Chief Executive Officer since December of 2016. ... experience, Mr. Bisaro, 56, is an accomplished global business ...
(Date:3/27/2017)... 27, 2017  PhaseRx, Inc. (NASDAQ: PZRX), a ... liver diseases in children, today reported financial results ... December 31, 2016 and provided an update on ... to make progress during the fourth quarter of ... our non-human primate safety study, and with our lead ...
Breaking Medicine Technology:
(Date:3/27/2017)... ... March 27, 2017 , ... The Anaheim Hills office ... First National Capital has added 10 new sales professionals over the past 6 months ... by 15 additional new hires over the course of 2017. , “This new ...
(Date:3/27/2017)... Orange, Texas (PRWEB) , ... March 27, 2017 ... ... celebration at the GTEC Orange facility from 8:00am-10:00am on Monday, April 3rd to ... giveaways and will be an opportunity for area-residents to celebrate two great years ...
(Date:3/26/2017)... ... March 26, 2017 , ... Local physician Dr. Justin ... a prestigious award honoring the top influencers on RealSelf—the most trusted online destination ... doctors and clinics. , In 2016, more than 82 million people visited RealSelf ...
(Date:3/24/2017)... ... March 24, 2017 , ... Vighter ... the same time by providing Prehospital Trauma Life Support (PHTLS) course scholarships to ... premier prehospital trauma education developed in cooperation with the American College of Surgeons ...
(Date:3/24/2017)... ... ... The Radiology Business Management Association (RBMA) has named the nine winners ... year, are among the most prestigious in radiology marketing because a panel of radiology ... recognize achievements in both large budget (over $5,000) and small budget (under $5,000) campaigns. ...
Breaking Medicine News(10 mins):